Grant ID RP160827
Awarded On May 18, 2016
Title A platform technology for the isolation of anti-cancer monoclonal antibodies from chickens
Program Academic Research
Award Mechanism High Impact/High Risk
Institution/Organization Texas A&M University System Health Science Center
Principal Investigator/Program Director Zhilei Chen
Cancer Sites All Sites
Contracted Amount $200,000
Lay Summary

Antibody-based therapy has transformed modern cancer treatment. However, to realize the full potential of antibodies in the fight against cancer, new and better cancer-cell-specific antibodies are urgently needed. All current therapeutic antibodies are derived from murine host. Mouse and human are both mammals and many of our proteins share high homology. Homologous regions likely play important cellular functions and thus are preserved through evolution. Hence, homologous regions on a cancer receptor are potentially good targets for cancer therapy. However, animals cannot generate antibodies against proteins of their own (a.k.a. “anti-self”). Consequently, it is not possible to obtain murin...

Read More